| Previous Close | 22.18 |
| Open | 22.15 |
| Volume | 581,961 |
| Avg. Volume (3M) | 1,299,942 |
| Market Cap | 14,095,976,448 |
| Price / Earnings (TTM) | 22.19 |
| Price / Earnings (Forward) | 15.60 |
| Price / Sales | 5.08 |
| Price / Book | 3.08 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2025 |
| Profit Margin | 23.69% |
| Operating Margin (TTM) | 38.25% |
| Diluted EPS (TTM) | 1.00 |
| Quarterly Revenue Growth (YOY) | 17.60% |
| Quarterly Earnings Growth (YOY) | -39.80% |
| Total Debt/Equity (MRQ) | 3.09% |
| Current Ratio (MRQ) | 5.17 |
| Operating Cash Flow (TTM) | 6.73 B |
| Levered Free Cash Flow (TTM) | 5.69 B |
| Return on Assets (TTM) | 10.95% |
| Return on Equity (TTM) | 14.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Genmab A/S | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.01% |
| % Held by Institutions | 8.42% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Harding Loevner Lp | 30 Sep 2024 | 3,066,942 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 125.33%) | Buy |
| Median | 49.00 (120.82%) | |
| Low | 48.00 (BMO Capital, 116.31%) | Buy |
| Average | 49.00 (120.82%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 22.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Jan 2025 | 50.00 (125.33%) | Buy | 22.19 |
| 16 Oct 2024 | 50.00 (125.33%) | Buy | 22.60 | |
| BMO Capital | 08 Nov 2024 | 48.00 (116.31%) | Buy | 23.08 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |